Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

30.75
-0.2150-0.69%
Volume:2.02M
Turnover:62.56M
Market Cap:35.82B
PE:25.41
High:31.39
Open:31.24
Low:30.58
Close:30.96
52wk High:37.35
52wk Low:12.47
Shares:1.17B
Float Shares:1.14B
Volume Ratio:0.73
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:20.79%
ROA:6.17%
PB:4.53
PE(LYR):25.41

Loading ...

Teva Pharmaceutical Indus Q4 Adj. EPS $0.96 Beats $0.68 Estimate, Sales $4.711B Beat $4.368B Estimate

Benzinga
·
Jan 28

Press Release: Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Dow Jones
·
Jan 28

Teva parnters iwth Will Forte to increase awareness of Huntington’s disease

TIPRANKS
·
Jan 27

Teva put volume heavy and directionally bearish

TIPRANKS
·
Jan 21

Earning Preview: Teva Pharmaceutical revenue is expected to increase by 4.95%, and institutional views are constructive

Earnings Agent
·
Jan 21

Neurocrine Biosciences Says Ingrezza Shows Greater Potency Than Austedo

MT Newswires Live
·
Jan 15

Analysts Are Bullish on Top Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Jan 15

Teva Pharmaceutical's Ajovy Reduces Migraine Days in Children

MT Newswires Live
·
Jan 15

Teva publishes Ajovy data in New England Journal of Medicine

TIPRANKS
·
Jan 15

Is Teva (TEVA) Still Reasonably Priced After A 195% Three Year Share Price Gain

Simply Wall St.
·
Jan 15

Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial

Benzinga_recent_news
·
Jan 14

UBS Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Jan 13

Israel’s Teva Pharmaceuticals (TEVA) Pops on Upbeat Guidance

TIPRANKS
·
Jan 13

Teva Stock Is Jumping. Why Investors Are So Optimistic on the Drugmaker. -- Barrons.com

Dow Jones
·
Jan 12

Teva Pharmaceutical Industries Reiterates 2025 Earnings, Revenue Guidance

MT Newswires Live
·
Jan 12

Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408

TIPRANKS
·
Jan 12

Barclays Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Jan 09

Truist Securities Adjusts Price Target on Teva Pharmaceutical Industries to $36 From $32, Maintains Buy Rating

MT Newswires Live
·
Jan 07

Teva Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
Jan 07

Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound

Simply Wall St.
·
Jan 05